OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Nasopharyngeal carcinoma is the most common malignant tumor of the nasopharynx, the upper part of the throat behind the nose and near the base of skull. A carcinoma is a cancer that starts in epithelial cells, the cells lining the internal and external surfaces of the body. A total of 63 NPC patients treated during the period 1990-2009 at the University Hospital Bonn, Germany, were included. The 5-year overall survival rate after concomitant chemoradiotherapy (RCT) was 75% and after radiotherapy (RT) 60%. The mortality rate increased by 3.5 times with each increase in T-stage (p=0.047). The recurrence rate (RR) after RCT was 34% and after RT alone 68% (p=0.04). Tumor ablation increased the RR significantly (p=0.047).
Treatment for nasopharyngeal carcinoma usually involves radiation therapy, chemotherapy or a combination of the two. In certain cases, surgery may be used to remove a tumor from the nasopharynx. This usually requires surgeons to make an incision in the roof of your mouth to access the area to remove the cancerous tissue.There is a need to conduct secondary prevention, such as improving rates of early detection, early diagnosis, and early treatment in NPC patients. Achievements in these areas might bring hope of providing a successful screening model in cancer.
